A semisynthetic cephamycin antibiotic that is administered intravenously or intramuscularly. The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative microorganisms. [PubChem]
Indication
For prophylaxis and treatment of bacterial infections.
Pharmacology
Cefotetan is a semisynthetic cephamycin antibiotic that is administered intravenously or intramuscularly. The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative microorganisms.
Affected Organisms
Enteric bacteria and other eubacteria
Biotransformation
No active metabolites of cefotetan have been detected; however, small amounts (less than 7%) of cefotetan in plasma and urine may be converted to its tautomer, which has antimicrobial activity similar to the parent drug.
Half Life
In volunteers with reduced renal function, the plasma half-life of cefotetan is prolonged
Protein Binding
Cefotetan is 88% plasma protein bound.
Elimination
No active metabolites of cefotetan have been detected; however, small amounts (less than 7%) of cefotetan in plasma and urine may be converted to its tautomer, which has antimicrobial activity similar to the parent drug. In normal patients, from 51% to 81% of an administered dose of Cefotetan is excreted unchanged by the kidneys over a 24 hour period, which results in high and prolonged urinary concentrations.
Distribution
* 10.4 L [elderly patients (greater than 65 years) with normal renal function] * 10.3 L [healthy volunteers (aged 25 to 28 years)]
Clearance
* 1.8 +/- 0.1 L/h [elderly patients with normal renal function (.65 years)] * 1.8 +/- 0.3 L/h [healthy volunteers (aged 25 to 28 years)]